Stem Cell

California Stem Cell Report
ViaCyte: Stem Cell Diabetes Therapy ‘Not Possible’ Without California Taxpayer Cash

ViaCyte: Stem Cell Diabetes Therapy ‘Not Possible’ Without California Taxpayer Cash

The California stem cell agency hit a couple of firsts this week when it pumped up its investment this week in the “teabag” diabetes therapy being developed by ViaCyte, Inc., of San Diego.

The effort, backed by $55 million from the agency, is the first clinical trial in the United States for a diabetes...

California Stem Cell Report
California Stem Cell Meeting Concludes; Links to Stories

BERKELEY, Ca. -- Directors of the California stem cell agency today concluded their meeting at 1:53 p.m. PDT. Look for more coverage of matters discussed at the meeting in the next week or so.

Here are links and excerpts from stories from today's session.

California Bets $55 Million on 'Teabag' Diabetes Treatment

BERKELEY, Ca. -- California...

California Stem Cell Report
Revolving Door Policy Tightened at California Stem Cell Agency

BERKELEY, Ca. -- Directors of the California stem cell agency today approved a measure aimed at easing conflicts of interest involving employees who may seek employment with recipients of the agency’s largess.


On a unanimous voice voice, the governing board  of the California Institute for Regenerative Medicine (CIRM) set a new revolving door...

California Stem Cell Report
CIRM Press Release on Viacyte Award on Diabetes

BERKELEY, Ca. -- The California stem cell has posted a press release on today's award to Viacyte, Inc., of San Diego, Ca., to speed up development of a human embryonic stem cell treatment for diabetes. Here is a link to the press release. 

California Stem Cell Report
California Bets $55 Million on ‘Teabag’ Diabetes Treatment

California Bets $55 Million on ‘Teabag’ Diabetes Treatment

BERKELEY, Ca. -- California today beefed up its investment in a “teabag” therapy for diabetes, bringing the total to $55 million in an effort to develop a “virtual cure” for an affliction that affects 347 million people worldwide.

It is believed to be the largest direct investment that the state has ever made in a...

California Stem Cell Report
California Stem Meeting Begins in Berkeley

BERKELEY, Ca. -- Directors of the $3 billion California stem cell agency opened their meeting this morning at 10:04 a.m. PDT with a "teabag" cure for  diabetes on their minds.Also on tap is consideration of a proposal to ease problems with conflic...

California Stem Cell Report
Coverage of California Stem Cell Meeting, Plus an Ohio Participation Possibility

The California Stem Cell Report will bring you on-the-scene, live, gavel-to-gavel coverage tomorrow of the meeting of the directors of the Golden State’s $3 billion stem cell research program.

Directors are expected to approve $16.6 million for a “teabag” treatment for diabetes that is being developed by Viacycte, Inc., of San Diego.  Also...

California Stem Cell Report
San Diego’s Viacyte Scoring Again with State Funding; Total Now Hits $55 Million

California’s stem cell research agency appears ready to pump another $16.6 million into a diabetes therapy effort that has already received $38.5 million from the Golden State.


At a total of more than $55 million, it is likely the single largest direct investment that the state of California has ever made in a business....

California Stem Cell Report
Tightening the Revolving Door at the California Stem Cell Agency

Tightening the Revolving Door at the California Stem Cell Agency

Directors of the California stem cell agency next week will consider a proposal aimed at partially addressing revolving-door and conflict-of-interest problems at the $3 billion research enterprise.


The proposal comes in the wake of a wave of unfavorable publicity this summer that embarrassed the agency when its former president, Alan Trounson, was named...

California Stem Cell Report
California’s New $200 Million Stem Cell Spark

California’s New $200 Million Stem Cell Spark

Directors of the $3 billion California stem cell agency this month will attempt to supercharge some of their major research programs and push stem cell therapies more rapidly into the marketplace and the clinic.


Sir John Bell
Academy of Medical Sciences photo
The move is part of a...

Stay connected to Sacramento Connect

Follow Sacramento Connect on Twitter  Find Sacramento Connect on Facebook  Sign up for the Sacramento Connect Newsletter

Advertisement

Categories

  • Hot Topics (2)
  • Shopping (798)
  • Top Stories (3423)

Advertisement